{"id":500167,"date":"2021-06-02T16:03:58","date_gmt":"2021-06-02T20:03:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/"},"modified":"2021-06-02T16:03:58","modified_gmt":"2021-06-02T20:03:58","slug":"kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/","title":{"rendered":"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., June  02, 2021  (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a virtual fireside chat at the Goldman Sachs 42<sup>nd<\/sup> Annual Global Healthcare Conference on Wednesday, June 9 at 4:40 p.m. ET.<\/p>\n<p align=\"left\">A live webcast of the event will be available under &#8220;Events and Presentations&#8221; in the Investors section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6cwY0HjZPlJSTDnOILGM_pcxG3Mh0CkLCk1qF_h3pQNohGo097OGxI3j1etn-gQZVy5Dk_TnlLtMsC6zDHcDuA==\" rel=\"nofollow noopener\" target=\"_blank\">www.kymeratx.com<\/a>. A replay of the webcast will be archived and available for one month following the event.<\/p>\n<p align=\"left\">\n        <strong>About Kymera Therapeutics<\/strong><br \/>\n        <br \/>Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera\u2019s Pegasus\u2122 platform enables the discovery of novel small molecule degraders designed to harness the body\u2019s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera\u2019s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R\/TLR or JAK\/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera\u2019s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.<\/p>\n<p align=\"left\">Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a \u201cFierce 15\u201d biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston\u2019s \u201cBest Places to Work.\u201d For more information about our people, science, and pipeline, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6cwY0HjZPlJSTDnOILGM_ptuFCP1PamFvGC6mxdyWMjeakTg0yG_bA7kA3tr6q2LcUZ059EwG_o1P37EsCmzvw==\" rel=\"nofollow noopener\" target=\"_blank\">www.kymeratx.com<\/a> or follow us on Twitter or LinkedIn.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Paul Cox<br \/>VP, Investor Relations and Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9jAPBFfLoQrFsATK6Vzs0UozXBKc7SMpSvQ-xOgCuQDOJrDZQ3lWP3fhLaGox7MJooGMSky3TcNCKi8w6UlFLA==\" rel=\"nofollow noopener\" target=\"_blank\">pcox@kymeratx.com<\/a><br \/>917-754-0207<\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Lissette L. Steele<br \/>Verge Scientific Communications for Kymera Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xBtrTd2jQUaG_FOBJVQ7NqjBa-z4HT4iJUXpKvqmnjVujfrqmJJFTRPgOP7iv3zyc5WG6kGUBn4Nj_bIsHmgvp8z6GTxai8wiv6RDoEDdBkuREUOSgms0WqQJPK_yKjG\" rel=\"nofollow noopener\" target=\"_blank\">lsteele@vergescientific.com<\/a><br \/>202-930-4762<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b0620e1b-43ba-4b33-8345-be83c49e7467\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9 at 4:40 p.m. ET. A live webcast of the event will be available under &#8220;Events and Presentations&#8221; in the Investors section of the Company&#8217;s website at www.kymeratx.com. A replay of the webcast will be archived and available for one month following the event. About Kymera Therapeutics Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-500167","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9 at 4:40 p.m. ET. A live webcast of the event will be available under &#8220;Events and Presentations&#8221; in the Investors section of the Company&#8217;s website at www.kymeratx.com. A replay of the webcast will be archived and available for one month following the event. About Kymera Therapeutics Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies &hellip; Continue reading &quot;Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-02T20:03:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference\",\"datePublished\":\"2021-06-02T20:03:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/\"},\"wordCount\":351,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/\",\"name\":\"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=\",\"datePublished\":\"2021-06-02T20:03:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference - Market Newsdesk","og_description":"WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9 at 4:40 p.m. ET. A live webcast of the event will be available under &#8220;Events and Presentations&#8221; in the Investors section of the Company&#8217;s website at www.kymeratx.com. A replay of the webcast will be archived and available for one month following the event. About Kymera Therapeutics Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies &hellip; Continue reading \"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-02T20:03:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference","datePublished":"2021-06-02T20:03:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/"},"wordCount":351,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/","name":"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=","datePublished":"2021-06-02T20:03:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzYwMSM0MjI0Mzc4IzIyMDA4MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/500167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=500167"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/500167\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=500167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=500167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=500167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}